Journal issue - WANFANG MED ONLINE

You Position: Home > Journal issue

Chinese Journal of Oncology

Issue 4, 2022

Items 1-5 of 11

«Preious | of 3 | Next»

Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer

Chinese Journal of Oncology, Volume 44, Issue 4,2022, Pages 364-369, doi:10.3760/cma.j.cn112152-20210226-00173

Pretreatment evaluation of 18F-FDG PET-CT in extranodal NK/T-cell lymphoma

Chinese Journal of Oncology, Volume 44, Issue 4,2022, Pages 370-376, doi:10.3760/cma.j.cn112152-20200525-00485

A real world study on the relationship between drug resistance of targeted therapy and prognosis of HER-2-positive advanced breast cancer

Chinese Journal of Oncology, Volume 44, Issue 4,2022, Pages 360-363, doi:10.3760/cma.j.cn112152-20200409-00325

Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

Chinese Journal of Oncology, Volume 44, Issue 4,2022, Pages 297-306, doi:10.3760/cma.j.cn112152-20220113-00033

Ultrasonographic features and clinical pathological of liver metastasis in patients with melanoma

Chinese Journal of Oncology, Volume 44, Issue 4,2022, Pages 354-359, doi:10.3760/cma.j.cn112152-20200305-00172

Items 1-5 of 11

«Preious | of 3 | Next»

2024:

2023:

2022:

2021:

2020:

2019:

2018:

2017:

2016:

2015:

2014:

2013:

2012:

2011:

2010:

2009:

2008:

2007:

2006:

2005:

2004:

2003:

2002:

2001:

2000: